TOP STORIES

• BUSINESS Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
  April 11, 2013

• BUSINESS Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
  April 10, 2013

• BUSINESS Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
  April 9, 2013

• REGULATORY MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
  April 8, 2013

• BUSINESS Takeda to Successively File 2 New Diabetes Drugs in Japan
  April 5, 2013

• BUSINESS Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
  April 4, 2013

• BUSINESS Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
  April 4, 2013

• BUSINESS Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
  April 3, 2013

• BUSINESS AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
  April 2, 2013

• BUSINESS DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
  April 2, 2013

• ORGANIZATION Pharma Officials Puzzled at Fuzzy Communications Provision in JPMA Code of Practice
  April 1, 2013

• REGULATORY MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
  March 29, 2013

• REGULATORY MHLW’s Generic Roadmap Compilation in Homestretch
  March 29, 2013

• BUSINESS Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
  March 28, 2013

• BUSINESS ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
  March 27, 2013

• BUSINESS New Settai Rules Halfway to Establishment; Some in Industry Want Further Rules as Well
  March 26, 2013

• BUSINESS Daiichi Sankyo Mulls Biz Platform after Olmesartan LOE: New 5 Year Plan
  March 25, 2013

• ORGANIZATION JPMA Officially Decides on One-Year Postponement of Individual Payment Disclosures under Transparency Guidelines
  March 22, 2013

• REGULATORY CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
  March 22, 2013

• ORGANIZATION JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
  March 22, 2013

ページ

• « 先頭
• ‹ Prev
• …
• 216
• 217
• 218
• 219
• 220
• 221
• 222
• 223
• 224
• …
• Next ›
• 最終 »